Open AccessHepatitis C virus: A global view
Author(s) -
Amal Ahmed Mohamed,
Tamer A Elbedewy,
Magdy ElSerafy,
Naglaa El-Toukhy,
Wesam Ahmed,
Zaniab Ali El Din
Publication year - 2015
Publication title -
world journal of hepatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v7.i26.2676
Subject(s) - medicine , hepatocellular carcinoma , sofosbuvir , cirrhosis , hepatitis c virus , pegylated interferon , hepatitis c , interferon , chronic hepatitis , liver disease , chronic liver disease , gastroenterology , virus , virology , ribavirin
Hepatitis C virus (HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease. Management of chronic HCV is aimed at preventing cirrhosis, reducing the risk of HCC, and treating extra hepatic complications. New treatments for chronic HCV has been devoted based on direct-acting antivirals, as pegylated interferon (peginterferon) is responsible for many side effects and limits treatment access. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens.